Alkermes plc. Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31)
Alkermes plc. (ALKS) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) of $594.00 thousand for the 12-month period ending 2013-03-31, per its 10-K filed 2013-05-23.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax · last filed 2013-05-23
- Alkermes plc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $594.00K.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2013-01-31) for fiscal 2013 was $594.00K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $0.00 derived: sum of 2 quarters · filed 2013-05-23 | $594.00K derived: sum of 3 quarters · filed 2013-05-23 | $594.00K 10-K · filed 2013-05-23 |
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $594.00K derived: sum of 2 quarters · filed 2013-01-31 | $594.00K 10-Q · filed 2013-01-31 | |
| 2012-09-30 | $594.00K 10-Q · filed 2012-11-01 | $594.00K 10-Q · filed 2012-11-01 | ||
| 2012-06-30 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |